Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Issues Earnings Results, Meets Estimates

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) announced its quarterly earnings results on Thursday. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03), FiscalAI reports. Lineage Cell Therapeutics had a negative net margin of 434.44% and a negative return on equity of 89.36%. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.84 million.

Here are the key takeaways from Lineage Cell Therapeutics’ conference call:

• Cash runway extended into Q3 2028: Lineage reported $50.8 million in cash, cash equivalents, and marketable securities, aided by a $4.6 million ATM raise. The company also cited potential additional funding from warrant exercises, Roche milestones, and future partnerships.
• OpRegen remains dependent on Roche/Genentech optimization work, particularly surgical delivery for the GAlette study, before a potential multicenter controlled trial. Lineage pointed to expanded study sites, EMA IRIS registration, and Roche’s conference activity as encouraging signals, but acknowledged these steps do not commit Roche to a European study or advancement.
• Lineage highlighted rapid expansion of its internally owned “Lineage 3.0” pipeline using the AlloSCOPE manufacturing platform. COR1 corneal endothelial cells are entering in vivo testing with initial data targeted by year-end, while the ILT1 diabetes program is focused on solving the large-scale islet manufacturing challenge.
• ReSonance, the auditory neuronal cell therapy partnered with Demant, has completed three engineering runs and its first GMP run, with release testing underway. Demant may fund up to $12 million of preclinical work intended to support an IND and/or CTA filing.
• Second-quarter revenue declined to $1.1 million from $2.8 million a year earlier, while R&D spending increased to $4.8 million as Lineage invested in preclinical programs. Reported net income of $1.5 million was primarily driven by a non-cash gain from warrant remeasurement rather than operating performance.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN:LCTX traded down $0.03 during midday trading on Friday, reaching $1.10. 227,112 shares of the company traded hands, compared to its average volume of 1,278,337. Lineage Cell Therapeutics has a twelve month low of $0.95 and a twelve month high of $2.09. The firm has a market capitalization of $275.48 million, a price-to-earnings ratio of -3.81 and a beta of 1.53. The company has a fifty day moving average price of $1.21 and a 200 day moving average price of $1.45.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. DLD Asset Management LP purchased a new position in Lineage Cell Therapeutics during the 4th quarter worth approximately $33,000. Kestra Advisory Services LLC lifted its stake in shares of Lineage Cell Therapeutics by 174.7% in the fourth quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock worth $46,000 after buying an additional 17,647 shares during the last quarter. Equitable Holdings Inc. bought a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter worth $51,000. Jump Financial LLC bought a new position in Lineage Cell Therapeutics in the 2nd quarter worth $28,000. Finally, Jain Global LLC raised its holdings in Lineage Cell Therapeutics by 202.3% in the 4th quarter. Jain Global LLC now owns 38,851 shares of the company’s stock worth $65,000 after acquiring an additional 26,000 shares during the period. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on LCTX. Canaccord Genuity Group assumed coverage on Lineage Cell Therapeutics in a report on Tuesday, April 28th. They issued a “buy” rating and a $9.00 price objective on the stock. D. Boral Capital reiterated a “buy” rating and issued a $3.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, May 4th. Finally, HC Wainwright restated a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Tuesday, July 14th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, Lineage Cell Therapeutics currently has an average rating of “Buy” and a consensus price target of $6.25.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.